

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Manfred Bohn et al.


Serial No. 09/077,194


Filing Date: May 26, 1998

**USE OF 1-HYDROXY-2-PYRIDONES
FOR THE TREATMENT OF
SEBORRHEIC DERMATITIS**

DECLARATION OF KEVIN KRIEL

I, Kevin Kriel, do hereby declare that:

- 
1. I have been employed by Medicis Pharmaceutical Corporation ("Medicis") since November 2002, and was a consultant to Medicis from January 2002 to November 2002. I am currently Senior Product Manager, and am responsible for the sales and marketing of Loprox® Shampoo. I am also a registered pharmacist and hold a degree in pharmacy from Albany College of Pharmacy. According to legal counsel, Loprox® Shampoo is a ciclopirox-containing shampoo covered by claims 38, 39, 40, 42, 48, 61, 63 and 64 of this patent application.
 2. My job responsibilities with respect to Loprox® Shampoo requires me to be familiar with seborrheic dermatitis, available treatments for seborrheic dermatitis, as well as the issues, preferences, and concerns that physicians and patients have concerning seborrheic dermatitis and treatments for it.
 3. No other ciclopirox shampoo is currently marketed in the U.S. to date.
 4. There are other seborrheic dermatitis treatments on the market in the U.S. They use a variety of active ingredients and delivery vehicles.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Reissue Patent Application of:
Bohn

Appln. Nos.: 09/077,194 and 10/606,229

Filing Date: December 4, 1998 and
June 26, 2003

Title: USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC
DERMATITIS

DECLARATION OF R. TODD PLOTT, M.D. UNDER 37 C.F.R. § 1.132

I, R. Todd Plott, M.D., being of legal age, declare as follows.

1. I am Vice President for Clinical Research and Regulatory Affairs of Medicis Pharmaceutical Corporation ("Medicis"). I am also a board certified dermatologist.
2. I received my undergraduate degree in Biology/Chemistry and History from Bethany Nazarene College and my M.D. from University of Texas Medical Branch in Galveston, Texas. My internship and residency in dermatology was at the University of Arkansas of Medical Sciences. My fellowship in dermatology was at the National Institutes of Health, National Cancer Institute.
3. After my fellowship, I was employed by Hoechst Roussel Pharmaceuticals and then Rhone-Poulenc Rorer Company (Dermik Laboratories, Inc.) as Director of Clinical Research. I then became Director, Worldwide Clinical Development for Galderma Laboratories, Inc. Then I was Director, Clinical Research in Dermatology and Anti-Infectives/Dermatology for Schering-Plough Research Institute. My employment at Medicis began in 2001. As can be seen, I have had significant experience in product development and clinical research in the field of dermatological products.
4. As Vice President of Medicis, my responsibilities include oversight of the development of new dermatological drug products, and of the preparation of applications for regulatory approval by the U.S. Food & Drug Administration.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Bohn et al.

Serial No. 09/077,194

Filed: December 4, 1998

Attorney Docket No.: 02-40045-US

USE OF 1-HYDROXY-2-PYRIDONES
FOR THE TREATMENT OF
SEBORRHEIC DERMATITIS

DECLARATION OF MITCHELL S. WORTZMAN, Ph.D.

I, Mitchell S. Wortzman, hereby declare as follows:

1. I am the Executive Vice President, Research and Development for Medicis Pharmaceutical Corporation ("Medicis"), and have been employed by Medicis since 1997. From 1980 to 1997, I was employed at Neutrogena Corporation, and was the President of the Dermatology Division starting in 1989.
2. Medicis is a licensee under this patent application.
3. Since 1980 I have been involved in the research and development for numerous dermatological products. My Ph.D. is in cellular and molecular biology from the University of Southern California.
4. I have reviewed the record in this application concerning the differences between dandruff and seborrheic dermatitis. The scientific literature of record correctly

605565

BEST AVAILABLE COPY